TLPH

Talphera, Inc. (TLPH) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Talphera, Inc. is a specialty pharmaceutical company focused on developing therapies for medically supervised settings. Its primary pipeline includes Niyad (a regional anticoagulant for dialysis circuits) and LTX-608 (a nafamostat formulation for IV infusion). The company operates as a non-accelerated filer and smaller reporting company.

Key Financial Metrics

Operating Expenses (YTD 2025): Research and Development was $2.67M; Selling, General, and Administrative (SG&A) was $3.97M.

Material Changes vs. Prior Period

• Reduced Burn Rate: Net loss decreased by approximately 9% for the quarter and 22% year-to-date compared to 2024, driven by headcount reductions and lower employee compensation.
• Cost Reductions: SG&A expenses decreased 23% year-to-date, aided by the Board of Directors agreeing to forego cash compensation through September 30, 2025, and reduced consulting fees.
• Capital Raise: In April 2025, the company completed the first tranche of a private placement, raising approximately $4.9 million in gross proceeds through the issuance of common stock and pre-funded warrants.
• Discontinued Operations: The company recognized $73,000 in net income from discontinued operations (DSUVIA) in the first half of 2025, compared to zero in the prior year period.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash resources are insufficient to fund operations for the next 12 months without additional capital.
• Financing Needs: The company expects to need additional capital prior to the 12-month anniversary of this filing. Plans include public/private equity offerings, debt, or strategic partnerships. Failure to secure funding could force workforce reductions or delays in clinical trials.
• Nasdaq Compliance: The company received a second 180-day grace period from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, extending until December 1, 2025. The company has transferred its listing to the Nasdaq Capital Market and may effect a reverse stock split if necessary.
• Clinical Progress: In March 2025, the FDA agreed to reduce the size of the Niyad NEPHRO CRRT registrational study from 166 to 70 patients. The company is also pursuing two additional tranches of its private placement contingent on patient enrollment milestones.
• Legal Proceedings: A securities class action lawsuit regarding DSUVIA marketing was dismissed with prejudice in May 2024, but plaintiffs have appealed. The appeal was under submission as of June 2025.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $6.79M cash balance against current burn rates and the timeline for the next capital raise.
• Private Placement Tranches: Monitor progress on the Niyad NEPHRO CRRT study enrollment to determine if the second and third tranches (potential $9.8M additional proceeds) will be triggered.
• Nasdaq Bid Price: Track the stock price to ensure it meets the $1.00 threshold for 10 consecutive days before the December 1, 2025 deadline to avoid delisting.
• DSUVIA Revenue: Assess the impact of Alora Pharmaceuticals discontinuing non-DoD sales efforts on future royalty payments and the "sale of future payments" liability.
• Supply Chain: Review risks associated with single-source suppliers for nafamostat active pharmaceutical ingredients (API) located in Japan and finished goods in China, particularly regarding tariffs and trade restrictions.